Analgesics

The market witnessed the shortage of some paediatric analgesics towards the end of the review period, causing alarm among parents in the Czech Republic. For example, the shortage of children's fever suppositories (Paralen Sup), which was most…

Since 2020, a factor supporting the growth of analgesics was the increased tendency of doctors to prescribe acetaminophen, among other common types of analgesics, as a way of managing the symptoms of patients with COVID-19, including muscle and joint…

In 2023, there have been stock shortages for some analgesics in key distribution channels in Saudi Arabia, resulting from producers, suppliers, and/or distributors. As a result, end consumers have been switching to alternative products containing the…

Despite general economic instability and a rise in prices, the analgesics category in 2023 looks set to achieve a positive performance. However, the current value growth rate is likely to be slower than in the previous year. This can be attributed to…

Analgesics recorded a significant increase in retail volume terms in 2021 and this was followed by even more dynamic growth in 2022. The COVID-19 pandemic and the tough restrictions introduced in 2020 and the beginning of 2021 in order to prevent it…

Demand for both adult and paediatric analgesics continued to grow in retail volume terms in 2023. Such products are widely used in Poland, particularly in the case of pain which is fleeting or immediate. With the rapid pace of modern life, consumers…

Analgesics has experienced a fluctuating performance in the last few years, as demand has been significantly impacted by the dramatic changes to consumer lifestyles resulting from the COVID-19 crisis. With the outbreak of COVID-19 in 2020, many…

Sales of analgesics return to their pre-pandemic performance in 2023. After the pandemic, seasonal colds and flus circulated more in the country as consumers socialised more without wearing masks, and sales of analgesics have returned to their usual…

Regional differences and the standard of living in the area greatly influences consumer buying behaviour. Regions have different cultural and social norms that impact the types of products that are purchased and the way they are marketed. For…

The pandemic boosted demand for analgesics in Vietnam, as consumers believed that it was necessary to store analgesics at home as a precautionary measure. Adult and paediatric acetaminophen performed particularly well in 2020 and 2021, as…

There are interesting developments in terms of diverging performances within adult systemic analgesics. In 2023, acetaminophen is set to drive current value growth, and significantly outpace the overall performance of adult analgesics. Growth in…

In the United Arab Emirates, analgesics can be categorised into two groups: products from international brands, and those from regional brands, which tend to be priced lower. By the end of the review period, the majority of analgesics brands were…

While most categories of analgesics are set to witness decreases in retail volume sales over 2023, this is largely due to spikes in sales in the wake of the Coronavirus (COVID-19) pandemic as stress and anxiety levels increased. In 2023, many…

Per capita consumption of analgesics continued to increase in Norway during 2023 after 2022 saw significant increases in consumption of these products. While there was some stockpiling of analgesics seen in Norway during the early stages of the…

Analgesics in Morocco has continued to develop positively in 2023, with total current value sales set to grow at a faster rate than in 2022 and most categories expected to post improved results in volume terms. Together with population growth and…

Analgesics is expected to see a single-digit growth in current value terms in 2023. Sales are benefiting from the stable demand for analgesics and unit price increases linked to rising price lists as a result of the higher cost of production faced by…

The return to normal lifestyles out of the home is driving retail volume and current value sales of analgesics in 2023. Adults and children alike are more exposed to common colds and viruses requiring pain relief. Children in school are no longer…

Analgesics sales are returning to more normal patterns in 2023, following the fluctuations caused by the COVID-19 pandemic and the sharp price rises seen in 2022. On balance, current value growth rates are still elevated compared to pre-pandemic…

Upon the lifting of all COVID-19 related regulations, including the compulsory use of face masks, social distancing rules and compulsory self-isolation, there has been a surge in illness which has been a major contributor to sales growth for…

Value sales of analgesics in France continue to record solid growth in 2023 following a dynamic performance the previous year. The key growth driver is the increasing demand for acetaminophen, with the brand Doliprane from Sanofi, convincingly…